Clinical Trial

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-08-23 -> 2029-07-01 2026-07-19
minor Completion pushed: 2027-08-23 -> 2029-07-01 2026-07-19
Trial Details
NCT Number NCT07030712
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Metastatic Neoplasm
Enrollment 67 participants
Start Date 2025-07-23
Primary Completion 2029-07-01 (estimated)
Study Completion 2029-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-17